News
1d
TipRanks on MSNGSK Executives Acquire Shares Under Reward Plan
GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...
The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.
Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...
GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to Rs 279 crore ...
1d
TipRanks on MSNGSK Enhances Shareholder Value with Strategic Buyback
GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK plc has announced the purchase of 494,426 of its own ordinary shares as part of ...
14d
GlobalData on MSNGSK’s speciality medicines soar while generals drop, Q2 results reveal
UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While the company’s total sales in this period totalled £8bn ...
GlaxoSmithKline Pharmaceuticals to launch oncology assets Jemperli and Zejula in India, addressing critical unmet needs in ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.97. The company’s shares opened today at p1,424.50. Take advantage of TipRanks Premium ...
In a report released today, Steve Scala from TD Cowen maintained a Hold rating on GlaxoSmithKline. The company’s shares closed yesterday at $37.67. Take advantage of TipRanks Premium at 50% off!
14d
Legit on MSNGSK reports improved outlook despite US drug tariffs
British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...
The FTSE 100 began Friday’s session on a positive note, gaining 23 points, reaching 9,124, as investors paid attention to ...
GlaxoSmithKline Pharmaceuticals Q1 net profit rises 12% to Rs 279 crore, despite slight dip in total income. Company highlights upcoming oncology drug launches.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results